View Older Stories View More Recent Stories

Nov 6, 2025 08:02AM Ionis presents long-term DAWNZERA data at ACAAI meeting
Nov 6, 2025 08:00AM Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
Oct 29, 2025 07:00AM Ionis reports third quarter 2025 financial results and highlights progress on key programs
Oct 27, 2025 07:00AM Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions
Oct 23, 2025 02:10PM Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture
Oct 21, 2025 08:00AM Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
Oct 16, 2025 07:05AM Ionis to hold third quarter 2025 financial results webcast
Oct 7, 2025 07:03AM Ionis hosts innovation day, targets sustained cash flow by 2028
Oct 7, 2025 07:00AM Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
Sep 22, 2025 07:00AM Ionis reports positive results for Alexander disease drug zilganersen
Sep 22, 2025 07:00AM Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
Sep 19, 2025 07:01AM TRYNGOLZA approved in Europe for rare genetic syndrome FCS
Sep 19, 2025 07:00AM TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
Sep 12, 2025 07:01AM Ionis expands adaptive event for neurological disease communities
Sep 12, 2025 07:00AM Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
Sep 9, 2025 07:00AM Ionis receives FDA breakthrough therapy designation for ION582
Sep 9, 2025 07:00AM Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
Sep 8, 2025 04:00PM Ionis to host investors and analysts for Innovation Day 2025
Sep 2, 2025 04:00PM Ionis to present at upcoming investor conferences
Sep 2, 2025 07:01AM Ionis olezarsen shows 72% triglyceride reduction in Phase 3 studies
Sep 2, 2025 07:00AM Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)
Aug 21, 2025 11:45AM DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
Jul 30, 2025 07:00AM Ionis reports second quarter 2025 financial results and highlights progress on key programs
Jul 25, 2025 07:15AM Ionis drug TRYNGOLZA gets EU committee approval recommendation for rare disease
Jul 25, 2025 07:15AM TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
Jul 21, 2025 07:00AM Ionis reports positive HAE treatment switch study results
Jul 21, 2025 07:00AM Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
Jul 16, 2025 07:05AM Ionis to hold second quarter 2025 financial results webcast
Jun 25, 2025 07:31AM Ionis Pharmaceuticals (IONS) announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
Jun 25, 2025 07:31AM Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
Jun 12, 2025 09:01AM Ionis Pharmaceuticals (IONS) Announces Retirement of Chief Development Officer
Jun 12, 2025 09:00AM Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
Jun 11, 2025 07:02AM Ionis Pharmaceuticals (IONS): First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
Jun 11, 2025 07:00AM First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
May 19, 2025 07:01AM Ionis Pharmaceuticals (IONS) announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
May 19, 2025 07:00AM Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
May 6, 2025 07:05AM Ionis to host 2025 virtual Annual Meeting of Stockholders
Apr 30, 2025 07:00AM Ionis reports first quarter 2025 financial results
Apr 29, 2025 07:00AM New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies
Apr 16, 2025 07:05AM Ionis to hold first quarter 2025 financial results webcast
Apr 3, 2025 07:05AM Ionis to host expert panel discussion on sHTG
Mar 31, 2025 07:05AM Ionis to present at upcoming investor conferences
Mar 26, 2025 07:02AM Ionis Pharmaceuticals (IONS) expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Mar 26, 2025 07:00AM Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Mar 11, 2025 06:13PM Ionis Pharmaceuticals (IONS) and Ono announce global license agreement
Mar 11, 2025 06:00PM Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
Mar 10, 2025 07:02AM Ionis Pharmaceuticals (IONS) Announces WAINZUA approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
Mar 10, 2025 07:00AM WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
Feb 25, 2025 07:05AM Ionis to present at upcoming investor conferences
Feb 20, 2025 07:03AM Ionis Pharmaceuticals (IONS): New positive donidalorsen data to be presented at AAAAI/WAO
View More Recent Stories View Older Stories